GSRX Industries Inc. (GSRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 100.0% |
| 2019 | -22.25 Million USD | 55.23% |
| 2018 | -16.8 Million USD | 35.57% |
| 2017 | - USD | -94554.38% |
| 2016 | -27.55 Thousand USD | 53.55% |
| 2015 | - USD | 0.11% |
| 2014 | -59.38 Thousand USD | -0.72% |
| 2013 | -58.96 Thousand USD | -4.04% |
| 2012 | -56.67 Thousand USD | 2.56% |
| 2011 | -58.16 Thousand USD | -2.63% |
| 2010 | -56.67 Thousand USD | -1.31% |
| 2009 | -55.93 Thousand USD | -11.24% |
| 2008 | -50.28 Thousand USD | -107.4% |
| 2007 | -24.24 Thousand USD | -468.04% |
| 2006 | -4268.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 Q3 | -1.47 Million USD | -637.23% |
| 2020 Q2 | 275.01 Thousand USD | 52.74% |
| 2020 FY | - USD | 100.0% |
| 2020 Q1 | 180.05 Thousand USD | -97.01% |
| 2019 FY | - USD | 55.23% |
| 2019 Q4 | 6.01 Million USD | 154.05% |
| 2019 Q3 | -11.13 Million USD | -1510.71% |
| 2019 Q2 | 789.48 Thousand USD | 124.72% |
| 2019 Q1 | -3.19 Million USD | -15.41% |
| 2018 Q4 | -2.76 Million USD | -46.04% |
| 2018 Q2 | -1.48 Million USD | 82.6% |
| 2018 Q1 | -8.5 Million USD | 61.54% |
| 2018 FY | - USD | 35.57% |
| 2018 Q3 | -1.89 Million USD | -28.0% |
| 2017 Q3 | -659.44 Thousand USD | 80.0% |
| 2017 FY | - USD | -94554.38% |
| 2017 Q1 | -17.06 Thousand USD | -15.16% |
| 2017 Q4 | -22.12 Million USD | -3255.3% |
| 2017 Q2 | -3.29 Million USD | -19226.04% |
| 2016 FY | - USD | 53.55% |
| 2016 Q3 | -13.83 Thousand USD | 6.09% |
| 2016 Q4 | -14.81 Thousand USD | -7.08% |
| 2016 Q2 | -14.73 Thousand USD | 13.82% |
| 2016 Q1 | -17.09 Thousand USD | -16.63% |
| 2015 Q3 | -13.9 Thousand USD | -0.48% |
| 2015 FY | - USD | 0.11% |
| 2015 Q4 | -14.65 Thousand USD | -5.41% |
| 2015 Q2 | -13.84 Thousand USD | 18.17% |
| 2015 Q1 | -16.91 Thousand USD | -18.47% |
| 2014 FY | - USD | -0.72% |
| 2014 Q4 | -14.27 Thousand USD | -3.22% |
| 2014 Q1 | -16.73 Thousand USD | -21.7% |
| 2014 Q3 | -13.83 Thousand USD | 4.93% |
| 2014 Q2 | -14.54 Thousand USD | 13.08% |
| 2013 Q4 | -13.75 Thousand USD | 0.58% |
| 2013 Q3 | -13.83 Thousand USD | -1.3% |
| 2013 Q2 | -13.65 Thousand USD | 22.96% |
| 2013 Q1 | -17.72 Thousand USD | -36.94% |
| 2013 FY | - USD | -4.04% |
| 2012 Q3 | -15.53 Thousand USD | -36.55% |
| 2012 Q4 | -12.94 Thousand USD | 16.69% |
| 2012 Q1 | -16.82 Thousand USD | -13.5% |
| 2012 Q2 | -11.37 Thousand USD | 32.36% |
| 2012 FY | - USD | 2.56% |
| 2011 Q2 | -12.7 Thousand USD | 30.22% |
| 2011 Q3 | -12.42 Thousand USD | 2.27% |
| 2011 Q4 | -14.82 Thousand USD | -19.32% |
| 2011 FY | - USD | -2.63% |
| 2011 Q1 | -18.21 Thousand USD | -40.22% |
| 2010 Q1 | -18.63 Thousand USD | -51.82% |
| 2010 Q3 | -12.58 Thousand USD | -1.07% |
| 2010 Q4 | -12.98 Thousand USD | -3.19% |
| 2010 FY | - USD | -1.31% |
| 2010 Q2 | -12.45 Thousand USD | 33.17% |
| 2009 Q4 | -12.27 Thousand USD | 7.87% |
| 2009 Q2 | -12.9 Thousand USD | 25.96% |
| 2009 Q1 | -17.43 Thousand USD | -5.34% |
| 2009 FY | - USD | -11.24% |
| 2009 Q3 | -13.32 Thousand USD | -3.25% |
| 2008 Q4 | -16.54 Thousand USD | -22.97% |
| 2008 FY | - USD | -107.4% |
| 2008 Q1 | -11.48 Thousand USD | -76.16% |
| 2008 Q2 | -8796.00 USD | 23.41% |
| 2008 Q3 | -13.45 Thousand USD | -52.98% |
| 2007 Q2 | -6339.00 USD | -13.12% |
| 2007 FY | - USD | -468.04% |
| 2007 Q1 | -5604.00 USD | 0.0% |
| 2007 Q3 | -5782.00 USD | 8.79% |
| 2007 Q4 | -6519.00 USD | -12.75% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bright Green Corporation | - USD | NaN% |
| BioQuest Corp. | -33.57 USD | 100.0% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 100.0% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 100.0% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 100.0% |
| High Sierra Technologies, Inc. | -181.97 Thousand USD | 100.0% |
| Instadose Pharma Corp. | - USD | NaN% |